The fact that this paper did not conclude that ER has an effect on secondary thyroid cancer in breast cancer patients may be related to the fact that gene-related variables were not included in this study, and that the SEER database contains only baseline and treatment information and no genetic data, which is a limitation that exists in this study31–33. This evidence concerns the gene ESR1 and breast carcinoma.